Users Discontinuing Anti-Obesity Injections Gain Back Weight at a Quadrupled Rate Than Dieters

A recent study indicates that people who stop using popular weight-loss injections like semaglutide or tirzepatide tend to recover shed pounds far faster than those who stop traditional diet and exercise plans.

Research printed in a major medical journal demonstrates that while obese individuals often shed a large proportion of their body weight while on the medication, the mass comes back at an average rate of 0.8 kg per month after stopping.

"Users using these treatments need to be informed of the risk of fast rebound weight gain when the medication is stopped," warns lead investigator Dr. Susan Jebb.

This pace of regain means a reversion to original weight in about one and a half years.

Weighing Therapies

The analysis, which reviewed dozens of trials involving thousands of patients, compared the effects of these new drugs with older methods.

The team emphasize that individuals who shed pounds through diet and exercise generally experience a slower weight regain—perhaps 100 grams monthly—after stopping.

The Reason for the Rapid Rebound

Nutrition scientists believe the way of the drugs accounts for the heightened regain.

The injections imitate a body's own chemical called GLP-1, which moderates feelings of fullness.

"Long-term administration of GLP-1 concentrations far above than the body's typical production may cause the system to produce less of its own natural hormone, and could diminish sensitivity to its effects," explained Dr. Adam Collins, a nutrition expert.

"Discontinuation of this medication leads to appetite is no longer kept in check, making overeating far more likely."

An Ongoing Disease?

Medical guidelines recommend the injections for individuals with obesity-related medical conditions, accompanied by prescribed lifestyle changes.

A number of clinicians contend that, considering the high risk of weight regain, the therapy should be considered life-long.

This perspective is echoed by pharmaceutical companies, who state that the results "emphasize the persistent nature of obesity," comparing it to managing diseases like hypertension.

Patient Testimonies

Individuals who have come off the jabs explain a powerful resurgence of appetite.

"I experienced something activating and I was suddenly extremely hungry," said one woman.

This challenge is worsened if patients have not adopted sustainable lifestyle or habit modifications during therapy.

Significant Interest

Survey data show that millions of adults in the UK have used these injections in the past year, with desire continuing to grow.

• Use is greater among females than men.
• The 40s and 50s demographic shows the greatest level of interest.
• Many obtain the medications through private prescriptions rather than public health services.

Finally, clinicians emphasize that while GLP-1 drugs are effective tools for shedding pounds, they are not a magic cure and long-term success relies on ongoing behavioural support.